GLS 5700

Drug Profile

GLS 5700

Alternative Names: GLS-5700; Zika dMAb® therapy

Latest Information Update: 01 Sep 2016

Price : $50

At a glance

  • Originator GeneOne Life Science; Inovio Pharmaceuticals
  • Class DNA vaccines; Monoclonal antibodies; Viral vaccines; Zika virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Zika virus infection

Most Recent Events

  • 29 Aug 2016 Clinical trials in Zika virus infection (In volunteers, Prevention) in Puerto Rico (Intradermal)
  • 29 Aug 2016 Inovio Pharmaceuticals completes enrolment in its phase I trial for Zika virus infections in USA and Canada (NCT02809443)
  • 26 Jul 2016 Health Canada approves IND application for GLS 5700 in Zika virus infection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top